Explorer les evidences

Palier Gold : evidences validées mécaniquement, avec leur source primaire.

68 evidences · page 3 / 3

149,4 per_100000The annual rate of cervical cancer deaths per 100,000 females in Senegal was 149.4 for the 80–84 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

105,2 per_100000The annual rate of cervical cancer cases per 100,000 females in Senegal was 105.2 for the 60–64 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

101 534 deathsIf HPV vaccination coverage in Senegal remains at current levels with Gardasil-4 and no further improvements are made, it is projected that 101,534 girls will die from cervical cancer over their lifetimes.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

100 %The most common HPV types identified in a cervical cancer surveillance study in Senegal between 2013 and 2017 were type 16 (100%), type 18 (83%), and type 45 (33%).

Sénégalcancer du col de l'utérus · infection à HPVobservé 2013–2017HAL · Unilimdocument de 111 observations

1 327 deathsAn estimated 1327 deaths from cervical cancer occurred in 2023.

Sénégalcancer du col de l'utérusobservé 2023HAL · Unilimdocument de 111 observations

22,5 %Among cervical cancer cases in Senegal, 22.5% were distant.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

0 %Stage-specific five-year survival rates for cervical cancer in Senegal were estimated at 0.0% for distant stage.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

1 517,35 USDThe total cost of cervical cancer treatment was estimated at USD 1517.35 for local stage, USD 2526.23 for regional stage, and USD 4114.16 for distant stage in Senegal.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

50,3 %The five-year survival rate for cervical cancer in the local stage is 50.3%.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

33,3 %The percentage distribution of cervical cancer by severity stage in Senegal was 33.3% for stages I and II.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

12 %Cecolin interventions were projected to reduce cervical cancer incidence by 12% to 16% over the cohort’s lifetime compared to the baseline.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

44,2 %Among cervical cancer cases in Senegal, 44.2% were regional.

Sénégalcancer du col de l'utérusHAL · Unilimdocument de 111 observations

15,2 per_100000The annual rate of cervical cancer cases per 100,000 females in Senegal was 15.2 for the 25–29 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

4,3 per_100000The annual rate of cervical cancer deaths per 100,000 females in Senegal was 4.3 for the 30–34 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

165,3 per_100000The annual rate of cervical cancer cases per 100,000 females in Senegal was 165.3 for the 85+ years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

83,5 per_100000The annual rate of cervical cancer cases per 100,000 females in Senegal was 83.5 for the 50–54 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

115,4 per_100000The annual rate of cervical cancer cases per 100,000 females in Senegal was 115.4 for the 65–69 years age group, according to GLOBOCAN 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

Cervical cancer incidence and mortality rates for Senegal were estimated by GLOBOCAN for the year 2022.

Sénégalcancer du col de l'utérusobservé 2022HAL · Unilimdocument de 111 observations

Chaque ligne mène à son document source. Le nombre indiqué est celui des observations VALIDÉES qu'il porte, jamais celui des observations extraites : les deux diffèrent sur la plupart des documents. L'extrait exact du texte source n'est pas publié, par contrainte de droit d'auteur.